UNSPSC 51373420: Carbetapentane/chlorpheniramine/citric/codeine/guaifenesin/sodium salicylate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373420 Carbetapentane/chlorpheniramine/citric/codeine/guaifenesin/sodium salicylate is a Commodity code under which state and local governments procure pharmaceutical products and related healthcare supplies, though recent solicitation activity shows material scope divergence from the code's nominal chemical formulation. The Washington State Department of Corrections and Seminole County, Florida have both posted opportunities tagged to this code that reflect acquisition of broader parenteral and emergency-response pharmaceutical products rather than the specific combination drug named in the code itself. State and local issuing bodies using this code include correctional agencies and county health departments, each with ongoing or recurring needs for controlled and non-controlled pharmaceutical supplies to support incarcerated populations and community health initiatives.

Recent activity concentrates in Washington and Florida. The Washington State Department of Corrections issued RFQ RFQQK13020 on September 8, 2026 for parenteral products, services, and equipment — including total parenteral nutrition (TPN and PPN) solutions, intravenous solutions, and other parenteral products including controlled substances — with response due October 7, 2026, seeking to supply eight facilities across three regions with delivery windows as tight as 24 hours for PN bags and 8 hours for other parenteral products; DOC anticipates multiple contractor awards, up to three per region, and includes set-aside goals for small businesses (25%), minority-owned (10%), women-owned (6%), and veteran-owned (5%) firms. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries and a July 26, 2023 response deadline. The code shows limited recent activity and material mismatch between its nominal scope and actual procurement; vendors should verify commodity alignment before committing resources to pursuit.